Previous close | 40.74 |
Open | 40.93 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 40.72 - 41.16 |
52-week range | 39.32 - 53.86 |
Volume | |
Avg. volume | 2,437,425 |
Market cap | 284.082B |
Beta (5Y monthly) | 0.31 |
PE ratio (TTM) | 18.60 |
EPS (TTM) | 2.21 |
Earnings date | N/A |
Forward dividend & yield | 1.24 (3.12%) |
Ex-dividend date | 17 Mar 2022 |
1y target est | 58.30 |
Data to be presented for the first time at ASCO and EHA 2022 show glofitamab induces high and durable complete response rates in people with heavily pre-treated diffuse large B-cell lymphoma 1Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphomaGlofitamab is part of Roche’s industry-leading CD20xCD3 bispecific antibody development programme, which aims to address the diverse needs and preferen
SOUTH SAN FRANCISCO, Calif., May 26, 2022--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new pivotal data on its investigational CD20xCD3 T-cell engaging bispecific antibody, glofitamab, will be presented for the first time at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7 and the European Hematology Association (EHA) 2022 Congress from June 9-12. Data from the Phase II NP30179 expansion study demonstrated that, afte
Roche's (RHHBY) Polivy combination receives the European Commission's approval for patients with previously untreated diffuse large B-cell lymphoma.